Would you consider adjuvant olaparib in a premenopausal female with TNBC with high risk features and germline BRCA1 mutation who achieved pCR after neoadjuvant chemotherapy?

Topics: Breast Cancer • Medical Oncology • Triple negative • Breast Cancer, Non-metastatic

Does not meet Olympia trial indication

Answer from: Medical Oncologist at Academic Institution

I would not, as these patients were not allowed to go on OlympiA. Their residual risk of TNBC relapse after PCR is low so the absolute benefit of olaparib for a year (if any) is also going to be low.

Comments

Medical Oncologist at NYU Winthrop Hospital
Thanks, Dr. @Hatem H. Soliman.

Related Questions